Malignant Digestive System Neoplasm

HSP27 (HSPB1) expression in pancreatic adenocarcinoma cell lines was associated with sensitivity to treatment with gemcitabine.

PMID 22004109 · Schäfer et al., 2012 · Open in CIViC

HSP110 (HSPH1) expression was immunohistochemically assessed using a tissue microarray in 210 gastric cancer patients. The overall survival rate was significantly lower in patients with high nuclear e… (full text at CIViC)

PMID 26943774 · Kimura et al., 2016 · Open in CIViC

49 patients gastric cancer patients treated with adjuvant chemotherapy were immunohistochemically assessed for nuclear HSPH1 (HSP110) expression. Overall survival rate in the high expression group (2+… (full text at CIViC)

PMID 26943774 · Kimura et al., 2016 · Open in CIViC

329 consecutive patients with stage II–III colorectal tumors with MSI after surgical resection at tertiary medical centers were screened for HSP110 T(17) by PCR. Patients underwent adjuvant chemothera… (full text at CIViC)

PMID 24512910 · Collura et al., 2014 · Open in CIViC

In a phase1 trial, 73 patients with cholangiocarcinoma harboring IDH1 mutations were treated with mutant IDH1 inhibitor ivosidenib. The response rate was 5%, median progression free survival was 3.8 m… (full text at CIViC)

PMID 31300360 · Lowery et al., 2019 · Open in CIViC

Through a high-throughput drug screen of a large panel of cancer cell lines, including 17 biliary tract cancers, this work found that IDH mutant (IDHm) ICC cells demonstrate a striking response to the… (full text at CIViC)

PMID 27231123 · Saha et al., 2016 · Open in CIViC

The multicenter randomized double-blind phase 3 study included patients with IDH1-mutant cholangiocarcinoma who had progressed on previous therapy. Patients were randomly assigned to Ivosidenib or pla… (full text at CIViC)

PMID 32416072 · Abou-Alfa et al., 2020 · Open in CIViC

A 48-year-old female was diagnosed with metastatic pancreatic ductal adenocarcinoma and subsequently started on standard of care chemotherapy, during which her hepatic lesions progressed. Detailed mol… (full text at CIViC)

PMID 27466707 · Brody et al., 2018 · Open in CIViC

In pancreatic cancer patients, ganitumab was associated with improved OS compared with placebo. The effect of ganitumab on improved OS was stronger for patients with higher levels of IGF-2. As Figur… (full text at CIViC)

PMID 23741071 · McCaffery et al., 2013 · Open in CIViC

Two human esophageal squamous cell carcinoma cell lines, KYSE170 and TE13, were transfected with the IL6 gene. These cell lines produced 5-6 fold (KYSE170) and 16-17 fold (TE13) IL6 compared to contr… (full text at CIViC)

PMID 21273582 · Suchi et al., 2011 · Open in CIViC

Cell lines with IRS2 copy number gain had higher levels of ligand-stimulated activation of IGF-1R and AKT. IRS2 siRNA knockdown reduced IRS2 protein expression levels and decreased sensitivity to BMS-… (full text at CIViC)

PMID 25527633 · Huang et al., 2015 · Open in CIViC

JAK1 mutations were identified by sequencing 60 HCC PDX tumour models. There mutations were then functionally characterized. HEK293FT cells were transfected with JAK1 WT or mutants (N451S, E483D, S703… (full text at CIViC)

PMID 26701727 · Yang et al., 2016 · Open in CIViC

JAK1 mutations were identified by sequencing 60 HCC PDX tumour models. There mutations were then functionally characterized. HEK293FT cells were transfected with JAK1 WT or mutants (N451S, E483D, S703… (full text at CIViC)

PMID 26701727 · Yang et al., 2016 · Open in CIViC

JAK1 mutations were identified by sequencing 60 HCC PDX tumour models. There mutations were then functionally characterized. HEK293FT cells were transfected with JAK1 WT or mutants (N451S, E483D, S703… (full text at CIViC)

PMID 26701727 · Yang et al., 2016 · Open in CIViC

A JAK1 S703I mutation was found to activate the JAK-STAT signaling pathway in vitro and in vivo in hepatocellular carcinoma. Ruxolitinib causes the suppression of JAK-STAT signaling pathway in PDX mod… (full text at CIViC)

PMID 26701727 · Yang et al., 2016 · Open in CIViC

This study finds JAK1 and JAK2 mutation as determinants of primary resistance to PD-1 blockade therapy. Baseline tumors from patients with melanoma and colon cancer who did not respond to PD-1 blockad… (full text at CIViC)

PMID 27903500 · Shin et al., 2017 · Open in CIViC

A 67-year-old female presents with recurrent metastatic colonic adenocarcinoma. Immunohistochemical and genetic workup showed overexpression of c-JUN and FOS, which presumably signals through the RAA… (full text at CIViC)

PMID 27022066 · Jones et al., 2016 · Open in CIViC

Case report of a 62-year old male patient diagnosed with pancreatic acinar cell carcinoma. Liver metastases were diagnosed and treatment was started with gemcitabine plus nab-paclitaxel regimen. After… (full text at CIViC)

PMID 35005993 · Gaule et al., 2022 · Open in CIViC

In this study, sensitivity to BET domain inhibitors was tested in KDM6A-null pancreatic cancer cell lines. The BET inhibitor was reported to inhibit the growth of KDM6A null cell lines upon transplant… (full text at CIViC)

PMID 29533787 · Andricovich et al., 2018 · Open in CIViC

COLO-320 colon cancer cells transfected with VEGFR2 (KDR) G800D caused tumor formation reaching the established humane endpoint in immune deficient mice, while empty vector and a kinase inactive VEGFR… (full text at CIViC)

PMID 29588308 · Toledo et al., 2018 · Open in CIViC

COLO-320 colon cancer cells transfected with VEGFR2 (KDR) G800R caused tumor formation reaching the established humane endpoint in immune deficient mice, while empty vector and a kinase inactive VEGFR… (full text at CIViC)

PMID 29588308 · Toledo et al., 2018 · Open in CIViC

COLO-320 colon cancer cells transfected with VEGFR2 (KDR) G843D caused tumor formation reaching the established humane endpoint in immune deficient mice, while empty vector and a kinase inactive VEGFR… (full text at CIViC)

PMID 29588308 · Toledo et al., 2018 · Open in CIViC

COLO-320 colon cancer cells transfected with VEGFR2 (KDR) L840F caused tumor formation reaching the established humane endpoint in immune deficient mice, while empty vector and a kinase inactive VEGFR… (full text at CIViC)

PMID 29588308 · Toledo et al., 2018 · Open in CIViC

COLO-320 colon cancer cells transfected with VEGFR2 (KDR) R1022Q caused tumor formation reaching the established humane endpoint in immune deficient mice, while empty vector and a kinase inactive VEGF… (full text at CIViC)

PMID 29588308 · Toledo et al., 2018 · Open in CIViC

COLO-320 colon cancer cells transfected with VEGFR2 (KDR) R1032Q caused tumor formation reaching the established humane endpoint in immune deficient mice, while empty vector and a kinase inactive VEGF… (full text at CIViC)

PMID 29588308 · Toledo et al., 2018 · Open in CIViC

R1032Q affects the gene's universal kinase catalytic motif. The authors found that injection of mice with COLO-320 cells that harbor this mutation resulted in tumor generation, indicating that this mu… (full text at CIViC)

PMID 29588308 · Toledo et al., 2018 · Open in CIViC

Case Report of a 84-year-old woman with stage IVb CRC after progression under 5-fluorouracil and bevacizumab. NGS revealed a frameshift mutation in APC, a missense mutation in KRAS. Variants of uncert… (full text at CIViC)

PMID 27004155 · Loaiza-Bonilla et al., 2016 · Open in CIViC

The colon cancer cell line COLO-320 was transfected with VEGFR2 (KDR) S1100F mutation. When injected into immune deficient mice, these cells were capable of causing tumor formation reaching the establ… (full text at CIViC)

PMID 29588308 · Toledo et al., 2018 · Open in CIViC

COLO-320 colon cancer cells transfected with VEGFR2 (KDR) S925F caused tumor formation reaching the established humane endpoint in immune deficient mice, while empty vector and a kinase inactive VEGFR… (full text at CIViC)

PMID 29588308 · Toledo et al., 2018 · Open in CIViC

KIF23 variant 1 was found to be expressed in the cDNA of tumor tissues from a large cohort of HCC patients of chinese descent via PCR. This expression was absent in the normal tissues of these patient… (full text at CIViC)

PMID 26674738 · Sun et al., 2015 · Open in CIViC

In a case study, a patient with anal melanoma harboring a 7 codon duplication in the juxtamambrane region (exon 11) of KIT showed marked response 4 months after imatinib treatment.

PMID 18421059 · Hodi et al., 2008 · Open in CIViC

Imatinib-resistant GIST882IR cells were derived by treating mice inoculated with GIST882 with imatinib over 6 passages. Western blots showed increased KIT protein expression in GIST882IR cells compare… (full text at CIViC)

PMID 26587973 · Lai et al., 2016 · Open in CIViC

High efficacy toward the imatinib-sensitive KITV559D mutant, with an IC50 of 82 nM. Also, decrease in KIT activation with an increasing dose of dasatinib (while total protein expression remaining unaf… (full text at CIViC)

PMID 21953054 · Emile et al., 2012 · Open in CIViC

In a retrospective TCGA cohort of microsatellite-instable colorectal adenocarcinoma (n = 43; KMT2D LOF = 16, WT = 27), KMT2D loss of function was associated with higher TMB (p < 0.001), higher neoanti… (full text at CIViC)

PMID 39578878 · Takemon et al., 2024 · Open in CIViC

In microsatellite-instable (MSI) colorectal carcinoma cell-line assays, KMT2D loss of function (LOF) stratified sensitivity to WRN perturbation. In DepMap viability data, WRN knockout was lethal in MS… (full text at CIViC)

PMID 39578878 · Takemon et al., 2024 · Open in CIViC

FFPE tumor tissue from 1506 colorectal adenocarcinoma patients was analyzed at codons 12, 13, 61 and 146 by PCR. 672 KRAS mutations were found in 670 patients, and from these, two were inframe inserti… (full text at CIViC)

PMID 24642870 · Tong et al., 2014 · Open in CIViC

A study of 419 patients with liver metastases of colorectal cancer identified 12 with A146 mutations. Compared to KRAS G12 tumors, patients with A146 positive tumors exhibited higher ctDNA levels. Pat… (full text at CIViC)

PMID 34820593 · van 't Erve et al., 2021 · Open in CIViC

This was a retrospective study of 605 patients with metastatic, chemotherapy refractory colorectal cancer treated with cetuximab + chemotherapy. Patients harboring KRAS codon 146 mutant tumors (n=11) … (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

In a systematic analysis of KRAS mutations across 2,280 KRAS-mutant colorectal cancer samples from three large clinical sequencing cohorts (DFCI, TCGA, MSKCC), KRAS A146P was confirmed as one of three… (full text at CIViC)

PMID 41299036 · Navarro-Jiménez et al., 2025 · Open in CIViC

Edkins et al. identified KRAS c.436G>C (p.A146P) in one primary colorectal cancer, PD1978a, during sequencing of two independent colorectal cancer cohorts. Normal DNA from the same individuals was ana… (full text at CIViC)

PMID 16969076 · Edkins et al., 2006 · Open in CIViC

The variant was found in 6 of 220 primary colorectal cancer patients. Found in 2 Colorectal Cancer cell lines: HCC2998 and LS1034 Found in 1 AML cell line: ML-2 Mutations of this residue presumably al… (full text at CIViC)

PMID 16969076 · Edkins et al., 2006 · Open in CIViC

In irinotecan-resistant metastatic colorectal cancer patients who had been treated with cetuximab and irinotecan, KRAS mutations in codon 61 or 146 were associated with shorter progression-free surviv… (full text at CIViC)

PMID 19603018 · Loupakis et al., 2009 · Open in CIViC